DK2963056T3 - Insulinanalog og anvendelse deraf - Google Patents
Insulinanalog og anvendelse deraf Download PDFInfo
- Publication number
- DK2963056T3 DK2963056T3 DK14757629.2T DK14757629T DK2963056T3 DK 2963056 T3 DK2963056 T3 DK 2963056T3 DK 14757629 T DK14757629 T DK 14757629T DK 2963056 T3 DK2963056 T3 DK 2963056T3
- Authority
- DK
- Denmark
- Prior art keywords
- application
- insulin analogue
- insulin
- analogue
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20130020703 | 2013-02-26 | ||
KR20130082511 | 2013-07-12 | ||
KR20140006937 | 2014-01-20 | ||
PCT/KR2014/001593 WO2014133324A1 (ko) | 2013-02-26 | 2014-02-26 | 신규한 인슐린 아날로그 및 이의 용도 |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2963056T3 true DK2963056T3 (da) | 2020-02-17 |
Family
ID=51428522
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK14757629.2T DK2963056T3 (da) | 2013-02-26 | 2014-02-26 | Insulinanalog og anvendelse deraf |
Country Status (25)
Country | Link |
---|---|
US (2) | US20160008483A1 (da) |
EP (2) | EP2963056B1 (da) |
JP (3) | JP6552968B2 (da) |
KR (2) | KR20140106452A (da) |
CN (2) | CN104995206B (da) |
AU (2) | AU2014221531B2 (da) |
BR (1) | BR112015019985A2 (da) |
CA (1) | CA2901873C (da) |
CL (1) | CL2015002330A1 (da) |
DK (1) | DK2963056T3 (da) |
ES (2) | ES2868351T3 (da) |
HK (1) | HK1211944A1 (da) |
IL (1) | IL240717B (da) |
MX (1) | MX366400B (da) |
MY (1) | MY186990A (da) |
PE (2) | PE20151409A1 (da) |
PH (1) | PH12015501814A1 (da) |
PT (1) | PT2963056T (da) |
RU (1) | RU2676729C2 (da) |
SA (2) | SA515360933B1 (da) |
SG (2) | SG10201907106VA (da) |
TW (3) | TWI708782B (da) |
UA (1) | UA119533C2 (da) |
WO (1) | WO2014133324A1 (da) |
ZA (1) | ZA201507104B (da) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20130049671A (ko) | 2011-11-04 | 2013-05-14 | 한미사이언스 주식회사 | 생리활성 폴리펩타이드 결합체 제조 방법 |
AR090281A1 (es) * | 2012-03-08 | 2014-10-29 | Hanmi Science Co Ltd | Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo |
KR20140106452A (ko) * | 2013-02-26 | 2014-09-03 | 한미약품 주식회사 | 신규한 인슐린 아날로그 및 이의 용도 |
MX369656B (es) * | 2014-01-20 | 2019-11-15 | Hanmi Pharm Ind Co Ltd | Insulina de accion prolongada y uso de la misma. |
AR100639A1 (es) | 2014-05-29 | 2016-10-19 | Hanmi Pharm Ind Co Ltd | Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada |
TWI684458B (zh) | 2014-05-30 | 2020-02-11 | 南韓商韓美藥品股份有限公司 | 包含胰島素及glp-1/昇糖素雙重促效劑之治療糖尿病之組成物 |
KR20150140177A (ko) | 2014-06-05 | 2015-12-15 | 한미약품 주식회사 | 단백질 및 펩타이드의 면역원성을 감소시키는 방법 |
KR20160101702A (ko) * | 2015-02-17 | 2016-08-25 | 한미약품 주식회사 | 지속형 인슐린 또는 이의 아날로그 결합체 |
EP3325496B1 (en) | 2015-07-24 | 2024-02-07 | Hanmi Pharm. Co., Ltd. | Method of preparing physiologically active polypeptide conjugate |
UY36870A (es) * | 2015-08-28 | 2017-03-31 | Hanmi Pharm Ind Co Ltd | Análogos de insulina novedosos |
US20180291077A1 (en) * | 2015-09-24 | 2018-10-11 | Hanmi Pharm. Co., Ltd | Method of insulin production |
US11396534B2 (en) | 2016-09-23 | 2022-07-26 | Hanmi Pharm. Co., Ltd. | Insulin analogs with reduced affinity to insulin receptor and use thereof |
JP2019536823A (ja) * | 2016-12-05 | 2019-12-19 | ハンミ ファーマシューティカル カンパニー リミテッド | 免疫反応が弱化された結合体 |
LT3551209T (lt) | 2016-12-09 | 2021-09-10 | Akston Biosciences Corporation | Insulino-fc suliejimai ir panaudojimo būdai |
JP2020506932A (ja) | 2017-02-03 | 2020-03-05 | ハンミ ファーマシューティカル カンパニー リミテッド | 持続性が増加した生理活性物質の結合体及びその用途 |
US11925691B2 (en) | 2017-02-07 | 2024-03-12 | Hanmi Pharm. Co., Ltd. | Non-peptidic polymeric linker compound, conjugate comprising same linker compound, and methods for preparing same linker compound and conjugate |
KR101941975B1 (ko) | 2017-03-17 | 2019-01-25 | 고려대학교 산학협력단 | Atpif1을 함유하는 당뇨 치료용 약학조성물 |
TWI798209B (zh) * | 2017-03-23 | 2023-04-11 | 南韓商韓美藥品股份有限公司 | 對胰島素受體有降低親和性之胰島素類似物之接合物及其用途 |
KR102612576B1 (ko) | 2017-09-29 | 2023-12-12 | 한미약품 주식회사 | 링커로서 비펩타이드성 중합체 결합 지방산 유도체 화합물을 포함하는 단백질 결합체 및 이의 제조방법 |
WO2019066603A1 (ko) | 2017-09-29 | 2019-04-04 | 한미약품 주식회사 | 효력이 향상된 지속성 단백질 결합체 |
US11267862B2 (en) | 2018-06-29 | 2022-03-08 | Akston Biosciences Corporation | Ultra-long acting insulin-Fc fusion proteins and methods of use |
DK4186920T3 (da) | 2018-06-29 | 2024-03-25 | Akston Biosciences Corp | Ultra-langtidsvirkende insulin-fc-fusionsproteiner og fremgangsmåder til anvendelse |
JP2022511567A (ja) | 2018-12-11 | 2022-01-31 | サノフイ | インスリンコンジュゲート |
CN113453703A (zh) | 2018-12-21 | 2021-09-28 | 韩美药品株式会社 | 包括胰岛素和对胰高血糖素和glp-1和gip受体均具有活性的三重激动剂的药物组合物 |
BR112021011557A2 (pt) | 2018-12-21 | 2021-09-14 | Hanmi Pharm. Co., Ltd. | Formulação complexa e composição farmacêutica incluindo insulina e glucagon |
TW202120536A (zh) * | 2019-07-31 | 2021-06-01 | 美商美國禮來大藥廠 | 鬆弛素(relaxin)類似物及其使用方法 |
JP7405486B2 (ja) | 2019-12-19 | 2023-12-26 | アクストン バイオサイエンシズ コーポレーション | 超長時間作用型インスリン-fc融合タンパク質および使用法 |
US11186623B2 (en) | 2019-12-24 | 2021-11-30 | Akston Bioscience Corporation | Ultra-long acting insulin-Fc fusion proteins and methods of use |
JP2023515247A (ja) * | 2020-03-31 | 2023-04-12 | ハンミ ファーマシューティカル カンパニー リミテッド | 新規な免疫活性インターロイキン2アナログ |
EP3972987B1 (en) | 2020-04-10 | 2023-06-07 | Akston Biosciences Corporation | Antigen specific immunotherapy for covid-19 fusion proteins and methods of use |
US11192930B2 (en) | 2020-04-10 | 2021-12-07 | Askton Bioscences Corporation | Ultra-long acting insulin-Fc fusion protein and methods of use |
JP2023534531A (ja) * | 2020-07-24 | 2023-08-09 | チアンスー ジェンサイエンス インコーポレイテッド | インスリン-Fc融合タンパク質及びその応用 |
US11667689B2 (en) | 2021-07-23 | 2023-06-06 | Akston Biosciences Corporation | Insulin-Fc fusion proteins and methods of use to treat cancer |
WO2023013638A1 (ja) * | 2021-08-02 | 2023-02-09 | Spiber株式会社 | 合成皮革及びその製造方法 |
CN117881691A (zh) * | 2021-08-02 | 2024-04-12 | 丝芭博株式会社 | 多孔质体及其制造方法 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
DE69731289D1 (de) | 1996-03-18 | 2004-11-25 | Univ Texas | Immunglobulinähnliche domäne mit erhöhten halbwertszeiten |
DE19735711C2 (de) * | 1997-08-18 | 2001-04-26 | Aventis Pharma Gmbh | Verfahren zur Herstellung eines Vorläufers von Insulin oder Insulinderivaten mit korrekt verbundenen Cystinbrücken |
US6660843B1 (en) * | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
JP2008169195A (ja) * | 2007-01-05 | 2008-07-24 | Hanmi Pharmaceutical Co Ltd | キャリア物質を用いたインスリン分泌ペプチド薬物結合体 |
CN101743252A (zh) * | 2007-07-16 | 2010-06-16 | 诺沃-诺迪斯克有限公司 | 蛋白酶稳定化的、peg化的胰岛素类似物 |
EP2376520B1 (en) * | 2008-12-19 | 2014-02-12 | Indiana University Research&Technology Corporation | Insulin analogs |
WO2011028813A2 (en) * | 2009-09-01 | 2011-03-10 | Case Western Reserve University | Insulin analogues of enhanced receptor-binding specificity |
AR081066A1 (es) * | 2010-04-02 | 2012-06-06 | Hanmi Holdings Co Ltd | Conjugado de insulina donde se usa un fragmento de inmunoglobulina |
KR101324828B1 (ko) * | 2010-06-08 | 2013-11-01 | 한미사이언스 주식회사 | 면역글로불린 단편을 이용한 단쇄 인슐린 아날로그 약물 결합체 |
AU2011282988A1 (en) * | 2010-07-28 | 2013-01-31 | Smartcells, Inc. | Recombinantly expressed insulin polypeptides and uses thereof |
UA113626C2 (xx) * | 2011-06-02 | 2017-02-27 | Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії | |
KR20140106452A (ko) * | 2013-02-26 | 2014-09-03 | 한미약품 주식회사 | 신규한 인슐린 아날로그 및 이의 용도 |
-
2014
- 2014-02-26 KR KR1020140022909A patent/KR20140106452A/ko not_active IP Right Cessation
- 2014-02-26 TW TW106143717A patent/TWI708782B/zh active
- 2014-02-26 US US14/769,495 patent/US20160008483A1/en not_active Abandoned
- 2014-02-26 TW TW103106674A patent/TWI621626B/zh active
- 2014-02-26 EP EP14757629.2A patent/EP2963056B1/en active Active
- 2014-02-26 UA UAA201507940A patent/UA119533C2/uk unknown
- 2014-02-26 CA CA2901873A patent/CA2901873C/en active Active
- 2014-02-26 PE PE2015001747A patent/PE20151409A1/es active IP Right Grant
- 2014-02-26 CN CN201480006998.4A patent/CN104995206B/zh active Active
- 2014-02-26 EP EP19197388.2A patent/EP3616727B1/en active Active
- 2014-02-26 CN CN202210291419.1A patent/CN114989289A/zh active Pending
- 2014-02-26 ES ES19197388T patent/ES2868351T3/es active Active
- 2014-02-26 PE PE2019001804A patent/PE20191481A1/es unknown
- 2014-02-26 SG SG10201907106VA patent/SG10201907106VA/en unknown
- 2014-02-26 AU AU2014221531A patent/AU2014221531B2/en active Active
- 2014-02-26 BR BR112015019985A patent/BR112015019985A2/pt active Search and Examination
- 2014-02-26 RU RU2015138536A patent/RU2676729C2/ru active
- 2014-02-26 MY MYPI2015001870A patent/MY186990A/en unknown
- 2014-02-26 PT PT147576292T patent/PT2963056T/pt unknown
- 2014-02-26 ES ES14757629T patent/ES2770776T3/es active Active
- 2014-02-26 MX MX2015010471A patent/MX366400B/es active IP Right Grant
- 2014-02-26 SG SG11201506095TA patent/SG11201506095TA/en unknown
- 2014-02-26 JP JP2015559199A patent/JP6552968B2/ja active Active
- 2014-02-26 DK DK14757629.2T patent/DK2963056T3/da active
- 2014-02-26 TW TW108100374A patent/TWI755579B/zh active
- 2014-02-26 WO PCT/KR2014/001593 patent/WO2014133324A1/ko active Application Filing
-
2015
- 2015-08-18 PH PH12015501814A patent/PH12015501814A1/en unknown
- 2015-08-19 CL CL2015002330A patent/CL2015002330A1/es unknown
- 2015-08-20 IL IL240717A patent/IL240717B/en active IP Right Grant
- 2015-08-23 SA SA515360933A patent/SA515360933B1/ar unknown
- 2015-08-23 SA SA518400491A patent/SA518400491B1/ar unknown
- 2015-09-25 ZA ZA2015/07104A patent/ZA201507104B/en unknown
- 2015-12-18 HK HK15112526.1A patent/HK1211944A1/xx unknown
-
2018
- 2018-05-18 US US15/983,923 patent/US20180256731A1/en not_active Abandoned
- 2018-11-22 AU AU2018267648A patent/AU2018267648B2/en active Active
-
2019
- 2019-07-03 JP JP2019124525A patent/JP2019187440A/ja active Pending
-
2021
- 2021-08-19 KR KR1020210109688A patent/KR102413691B1/ko active IP Right Grant
- 2021-08-19 JP JP2021133932A patent/JP2021193089A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2963056T3 (da) | Insulinanalog og anvendelse deraf | |
DK3043784T3 (da) | Arylethere og anvendelser deraf | |
DK2968443T3 (da) | Hepcidinanaloger og anvendelser deraf | |
DK2970460T3 (da) | Anti-IL-33-antistoffer og anvendelser deraf | |
DK3052181T3 (da) | Mikronåleplastre og systemer | |
DK3089994T3 (da) | Fabs-in-tandem-immunglobulin og anvendelser deraf | |
DK3027209T3 (da) | Anti-Activin A-antistoffer og anvendelser deraf | |
DK3003039T3 (da) | Methyl/fluor-pyridinyl-metoxy-substituerede pyridinon-pyridinyl-forbindelser og fluor-pyrimidinyl-metoxy-substituerede pyridinon-pyridinyl-forbindelser | |
DK3008168T3 (da) | Sc-celler og sammensætninger og fremgangsmåde til dannelse deraf | |
DK3052485T3 (da) | Heterocykliske forbindelser og anvendelser deraf | |
DK2962100T3 (da) | Tuberkulosebiomarkører og anvendelser deraf | |
DK3077467T3 (da) | Sikkativsammensætning og anvendelse deraf | |
DK3063144T3 (da) | Antiparasitære og pesticid-isoxazolinforbindelser | |
DK2968173T3 (da) | Heterocykliske forbindelser og anvendelser deraf | |
DK3030549T3 (da) | Pyridazinonforbindelser og anvendelser deraf | |
DK3003117T3 (da) | Videolaryngoskop og laryngoskopindføringsdel | |
DK3029038T3 (da) | Tetrazolinonforbindelse og anvendelse deraf | |
DK3053119T3 (da) | Papirløs anvendelse | |
DK2964767T3 (da) | Toksingener og fremgangsmåder til anvendelse deraf | |
DK3011041T3 (da) | Biodieselsammensætning og dermed forbundet fremgangsmåde og produkter | |
DK3058936T3 (da) | Peptidsammensætning og anvendelser deraf | |
DK2958926T3 (da) | Epidithiodioxopiperazinforbindelse eller derivater deraf og anvendelse deraf | |
DK3022361T4 (da) | Rambuk og fremgangsmåde til anvendelse deraf | |
DK2947141T3 (da) | Mikroorganismer der fremstiller docosahexaensyre og anvendelse deraf | |
DK2981316T3 (da) | Injektionssprøjte og et tilbehør dertil |